SPIN is steered by a Scientific Committee that supervises the good development of the Psoriasis International Network. The coordinators of the Scientific Committee represent the committee within the FRT - Fondation Rene Touraine’s Scientific Board.
The mission of the SPIN Committee is to develop the activities of the network, in particular by proposing international collaborative projects, contributing to continuing medical training in the field of skin inflammation and providing support to the development of national and regional networks.
Coordinators of SPIN Scientific Committee
-
President
Phyllis SPULSMD, PhD, Consultant Dermatologist at The Academic Medical Centre of the University of Amsterdam, NL
-
President-elect
Selection in progress -
Past-president
Jo LAMBERTChair Department of Dermatology, Ghent University Hospital, Belgium
-
President FRT Scientific Board
Thomas LUGERChair of Department of Dermatology, University of Münster, Germany
Members of the committee (by alphabetical order)
Martine BAGOT
Professor and Chairperson, Dermatology Department and INSERM U976, Hôpital Saint Louis, Paris, France
José Manuel CARRASCOSA
Associate Professor Department of Dermatology, Universitary Hospital Germans Trias I Pujol, Badalona, Spain
Romana CEOVIC
MD, PhD, University Department of Dermatovenerology, Zagreb Clinical Hospital and School of Medicine, Zagreb, Croatia
Elke DE JONG
Dermatologist at University Medical Center Nijmegen St Radboud, The Netherlands
Nejib DOSS
Head of the department of Dermatology – Military Hospital of Tunis, Professor Faculty of Medicine Tunis, Tunisia
Emad ELGAMAL
Professor of Dermatology, Venereology and Andrology, Damietta Faculty of Medicine, Al-Azhar University, New Damietta, Egypt
Carsten FLOHR
Professor Carsten Flohr, chair in dermatology and population science, St
John’s Institute of Dermatology, King’s college london
Maria Lorna FREZ
MD, Professor in Dermatology, University of the Philippines College of Medicine – Philippine General Hospital, Philippines
César GONZALEZ
Coordinator Grupo Colombiano de Psoriasis y artritis psoriasica (CoLPsor), Colombia
Alice GOTTLIEB
MD, PhD, Chair of Dermatology, Tufts Medical Centre, Boston, Massachusetts, USA
Christopher EM GRIFFITHS
MD FRCP FMedSci, Professor of Dermatology, The University of Manchester, Manchester Academic Health Science Centre, The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, UK
Jan Gutermuth
Professor Jan Gutermuth studied medicine at the Johannes Gutenberg-University Mainz/ Germany and trained in dermatology and allergology at the Humboldt University Berlin (Charité) and Technische University Munich (TUM).
Rolland GYULAI
MD, PhD, Director and chair of the Department of Dermatology, Venerology and Dermatooncology, University of Pécs, Hungary
Kenji KABASHIMA
Pr. Kenji KABASHIMA, Chairman and Head, Department of Dermatology, Kyoto University Graduate School of Medicine, Japan.
Lajos KEMENY
Professor and Chair of the Department of Dermatology and Allergology, University of Szeged, Hungary
Alur S. KUMAR
Professor and Head of Department, Owaisi Hospital Deccan College of Medical Sciences, Hyderabad, India
Richard LANGLEY
MD, FRCPC, Professor of Medicine (Dermatology) and Director of Research, Division of Dermatology, Department of Medicine, Dalhousie University, Canada
Mark LEBWOHL
MD, Sol and Clara Kest Professor and Chairman, Department of Dermatology Icahn School of Medicine at Mount Sinai, New York, NY, USA
Fatimata LY
Head of the Dermatology Department at the Institute of Social Hygiene in Dakar, Professor of Dermatology at the University Cheikh Anta Diop of Dakar, Senegal
Alan MENTER
Chair of research for Dermatology at Baylor Research Institute, Clinical Professor of Dermatology at the University of Texas Southwestern Medical School in Dallas and Professor at Texas A&M Health Science Center, College of Medicine, USA
Ulrich MROWIETZ
MD, Head of Psoriasis-Center, Dept. of Dermatology, Venerology and Allergology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany
Luigi NALDI
Director of Centro Studi GISED, Fondazione per la Ricerca Ospedale Maggiore, Bergamo, Italy
Alexander NAST
Department of Dermatology, Venerology and Allergy, Charité – Universitätsmedizin Berlin, Germany
Carle PAUL
Chair of Department of Dermatology, Paul Sabatier University, CHU Larrey, Toulouse, France
Jörg Christoph PRINZ
Univ.-Prof. Dr. med. Univ. Jörg Christoph PRINZ, Clinic for Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany
Luis PUIG
MD, PhD, Department of Dermatology, Hospital de la Sanat Creu i Sant Pau, Barcelona, Spain
Kristian REICH
Professor of Dermatology at the Georg-August-University Göttingen and at the Dermatologikum Berlin in Germany
Hugo SCHONENBERGER DE OLIVEIRA
MD University Dermatology Clinic, Coimbra University Hospital, Portugal
Lone SKOV
Professor, Consultant, Department of Dermato-Allergology, Gentofte Hospital,
Faculty of Health Sciences, University of Copenhagen, Denmark
Mona STAHLE
Professor of Dermatology and Venereology, Department of Medicine, Solna Karolinska Institute, Stockholm, Sweden
Diamant THAÇI
Professor and Head Comprehensive Center for Inflammation Medicine, University Luebeck, Germany
Jacob THYSSEN
Dr Thyssen is a clinical dermatologist and Professor employed by the
Capital Region and University of Copenhagen in Denmark.
Skaidra VALIUKEVICIENE
Professor and Head of the Department of Skin and Venereal Diseases, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
Peter VAN DE KERKHOF
Chief of the Department of Dermatology, Radboud University Nijmegen Medical Centre, The Netherlands
Christian VESTERGAARD
Aarhus University Hospital | AUH · Department of Dermatology
Richard WARREN
NIHR Clinical Senior Lecturer in Dermatology, Dermatology Centre, University of Manchester, Honorary Consultant Dermatologist Salford Royal NHS Foundation Trust, Manchester, UK
ZHENG Min
Professor and Chairman of the Department of Dermatology at Zhejiang University School of Medicine, China
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Matrix metalloproteinase-7 could be a predictor for acute inflammation in psoriatic patients.
Cytokine.
2020 Oct , 134:155195.
The pathogenesis of psoriasis is characterized by a disruption of extracellular matrix (ECM) in which matrix metalloproteinases (MMPs) participate actively. We aimed to determine MMP-7 level and its association with the inflammatory response in order to determine its usefulness as a biomarker for psoriasis prediction. We also aimed to determine its distribution in uninvolved and involved psoriatic skin to evaluate the probable role of MMP-7 in psoriasis (...)
see on pubmed
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Drug Deliv.
2020 Dec , 27, (1):662-680.
Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and (...)
see on pubmed
In silico data mining of large-scale databases for the virtual screening of human interleukin-2 inhibitors.
Acta Pharm.
2021 Mar 01, 71, (1):33-56.
Interleukin-2 (IL-2) is involved in the activation and differentiation of T-helper cells. Uncontrolled activated T cells play a key role in the pathophysiology by stimulating inflammation and autoimmune diseases like arthritis, psoriasis and Crohn's disease. T cells activation can be suppressed either by preventing IL-2 production or blocking the IL-2 interaction with its receptor. Hence, IL-2 is now emerging as a target for novel therapeutic approaches in several autoimmune disorders. This (...)
see on pubmed
on Atopic Dermatitis
Diagnostic Models for Atopic Dermatitis Based on Serum Microbial Extracellular Vesicle Metagenomic Analysis: A Pilot Study.
Allergy Asthma Immunol Res.
2020 Sep , 12, (5):792-805.
Associations between a wide variety of diseases and the microbiome have been extensively verified. Recently, there has been a rising interest in the role the microbiome plays in atopic dermatitis (AD). Furthermore, metagenomic analysis of microbe-derived extracellular vesicles (EVs) has revealed the importance and relevance of microbial EVs in human health.
see on pubmed
Mitochondrial and Nuclear Mitochondrial Variants in Allergic Diseases.
Jang H et al.
Mitochondrial and Nuclear Mitochondrial Variants in Allergic Diseases.
Allergy Asthma Immunol Res.
2020 Sep , 12, (5):877-884.
The mitochondrial genome encodes core catalytic peptides that affect major metabolic processes within a cell. Here, we investigated the association between mitochondrial DNA (mtDNA) variants and allergic diseases, including atopic dermatitis (AD) and asthma, alongside heteroplasmy within the mtDNA in subjects with allergic sensitization. We collected genotype data from 973 subjects with allergic sensitization, consisting of 632 children with AD, 498 children with asthma, and 481 healthy (...)
see on pubmed
Update on canine filaggrin: a review.
Combarros D et al.
Update on canine filaggrin: a review.
Vet Q.
2020 Dec , 40, (1):162-168.
Human filaggrin (FLG) plays a key role in epidermal barrier function, and loss-of-function mutations of its gene are primarily responsible for the development of human atopic dermatitis (AD). FLG expression is also reduced in the epidermis of atopic patients, due to the transcriptional effect of Th2 type cytokines. Canine atopic dermatitis (CAD) is a prevalent skin disease that shares many clinical and pathogenic features with its human homologue. The aim of this review is discuss current (...)
see on pubmed
